Trevi Therapeutics, Inc.
TRVI- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001563880
In the last 90 days, Trevi Therapeutics, Inc. insiders filed 0 open-market purchases and 1 sale; 218 institutions reported holding it in 13F filings for Q2 2026, worth $2.76B in total; Viking Global Investors is the only superinvestor holding it.
13F holders, Q4 2024
Institutional positions in Trevi Therapeutics, Inc. as of Dec 31, 2024. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 110
- +19 vs. Q3 2024
- Shares held
- 79.5M
- +21.5M (+37.0%) vs. Q3 2024
- Total value
- $329.5M
- +$135.8M (+70.1%) vs. Q3 2024
- New holders
- 26
- 47 more added
- Sold out
- 7
- 24 more reduced
2 institutions that held it in Q3 2024 haven't filed for Q4 2024 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.
Compare with Q3 2024: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting TRVI on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 218 | $2.76B |
| Q1 2026 | 198 | $1.61B |
| Q4 2025 | 184 | $1.63B |
| Q3 2025 | 164 | $1.18B |
| Q2 2025 | 154 | $627.2M |
| Q1 2025 | 137 | $554.3M |
| Q4 2024 | 110 | $329.5M |
| Q3 2024 | 93 | $194.1M |
| Q2 2024 | 77 | $166.6M |
| Q1 2024 | 80 | $177.9M |
| Q4 2023 | 63 | $70.0M |
| Q3 2023 | 55 | $106.1M |
| Q2 2023 | 53 | $116.7M |
| Q1 2023 | 36 | $80.4M |
| Q4 2022 | 37 | $83.3M |
| Q3 2022 | 40 | $70.5M |
| Q2 2022 | 32 | $80.8M |
| Q1 2022 | 23 | $32.9M |
| Q4 2021 | 17 | $10.3M |
| Q3 2021 | 18 | $17.4M |
| Q2 2021 | 17 | $28.1M |
| Q1 2021 | 19 | $35.6M |
Institutions, Q4 2024
Shares, value and share of portfolio for each institution holding Trevi Therapeutics, Inc.; share changes are against Q3 2024.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| MPM Oncology Impact Management LP | 3,094,896 | $12.8M | 1.81% | +1,556,379+101.2% | Added |
| Woodline Partners LP | 3,212,597 | $13.2M | 0.09% | +2,606,370+429.9% | Added |
| Vivo Capital, LLC | 3,487,903 | $14.4M | 1.61% | +1,875,000+116.3% | Added |
| Vanguard Group Inc | 3,509,213 | $14.5M | 0.00% | +246,832+7.6% | Added |
| BlackRock, Inc. | 3,928,462 | $16.2M | 0.00% | +706,710+21.9% | Added |
| Point72 Asset Management, L.P. | 4,150,237 | $17.1M | 0.05% | +4,150,237 | New |
| Rubric Capital Management LP | 4,205,129 | $17.3M | 0.32% | −821,802−16.3% | Reduced |
| Viking Global Investors LPSuperinvestorViking Global Investors | 4,400,000 | $18.1M | 0.06% | 00.0% | Unchanged |
| Frazier Life Sciences Management, L.P. | 10,664,774 | $43.9M | 1.82% | +3,283,684+44.5% | Added |
| NEA Management Company, LLC | 11,370,376 | $48.8M | 2.76% | 00.0% | Unchanged |
| Shay Capital LLC | 0 | $0 | 0.00% | −93,962−100.0% | Sold out |
| Fred Alger Management, LLC | 0 | $0 | 0.00% | −76,544−100.0% | Sold out |
| Bailard, Inc. | 0 | $0 | 0.00% | −35,133−100.0% | Sold out |
| Jane Street Group, LLC | 0 | $0 | 0.00% | −32,929−100.0% | Sold out |
| Federated Hermes, Inc. | 0 | $0 | 0.00% | −598−100.0% | Sold out |
| Capital Performance Advisors LLP | 0 | $0 | 0.00% | −134−100.0% | Sold out |
| Nisa Investment Advisors, LLC | 0 | $0 | 0.00% | −84−100.0% | Sold out |
| Raymond James & Associates | – | – | – | – | Not filed |
| AJOVista, LLC | – | – | – | – | Not filed |